首页|真武汤加减治疗慢性心力衰竭合并利尿剂抵抗的Meta分析

真武汤加减治疗慢性心力衰竭合并利尿剂抵抗的Meta分析

扫码查看
目的 系统评价真武汤加减联合西药常规治疗慢性心力衰竭(Chronic heart failure,CHF)合并利尿剂抵抗(Diuretic resistance,DR)的临床疗效.方法 检索自建库起至2023年11月1日中国知网、万方数据库、维普数据库、中国生物医学文献数据库、PubMed、Cochrane Library、Embase、Web of Science、Clinical Trials、中国临床试验注册中心等数据库中真武汤加减治疗CHF合并DR的随机对照试验,采用Review Manager 5.4软件对文献数据进行Meta分析.结果 共纳入15篇文献,包括1187例患者.Meta分析结果显示,与单纯西药对照组相比,真武汤加减联合西药常规治疗组患者在24 h总尿量[n=1058,MD=397.30,95%CI(269.44,525.16),P<0.01]、临床总有效率[n=625,RR=1.24,95%CI(1.15,1.34),P<0.01]、左心室射血分数(Left ventricular ejection frac-tions,LVEF)[n=697,MD=4.32,95%CI(2.51,6.112),P<0.01]、氨基末端脑利钠肽前体(N-terminal pro-B-type natriuretic peptide,NT-proBNP)水平[n=282,MD=734.4,95%CI(828.93,639.87),P<0.01]、外周血 IL-6水平[n=170,MD=-5.70,95%CI(-7.23,-4.16),P<0.01]、外周血 TNF-α 水平[n=170,MD=-12.79,95%CI(-15.53,-10.04),P<0.01]方面均有明显改善,而左室舒张末内径未见明显改善[n=266,MD=-4.50,95%CI(-9.36,0.35),P=0.07].药物安全性良好,加载中药治疗可显著降低低钾血症发生率[n=177,RR=0.32,95%CI(0.18,0.57),P<0.01].结论 在单纯西药治疗基础上,予真武汤加减可改善CHF合并DR患者24 h尿量、提高临床总有效率、改善患者心功能、降低炎症因子水平,且安全性较好.
Meta-Analysis of Modified Zhenwu Decoction in Treatment of Diuretic Resistance in Heart Failure
Objective To systematically evaluate the clinical efficacy of modified Zhenwu Decoction combined with conventional western medicine in the treatment of diuretic resistance in heart failure.Methods The randomized con-trolled trials of modified Zhenwu Decoction in the treatment of diuretic resistance in heart failure were searched from CNKI,Wanfang Database,VIP Database,China Biomedical Literature Database,PubMed,Cochrane Library,Embase,Web of Science,Clinical Trials,China Clinical Trial Registry,and other databases from their establishment to November 1,2023.Review Manager 5.4 software was used for the Meta-analysis of the data from the literature.Results A total of 15 pieces of literature were included,involving 1 187 patients.Meta-analysis showed that compared with those in the western medicine control group,the total 24 h urine volume[n=1 058,MD=397.30,95%CI(269.44,525.16),P<0.01],total clinical effective rate[n=625,RR=1.24,95%CI(1.15,1.34),P<0.01],left ventricular ejection fractions(LVEF)[n=697,MD=4.32,95%CI(2.51,6.112),P<0.01],level of N-terminal pro-B-type natriuretic peptide(NT-proBNP)[n=282,MD=734.4,95%CI(828.93,639.87),P<0.01],IL-6 level in peripheral blood[n=170,MD=-5.70,95%CI(-7.23,-4.16),P<0.01],and TNF-α level in peripheral blood[n=170,MD=-12.79,95%CI(-15.53,-10.04),P<0.01]in the modified Zhenwu Decoction combined with conventional western medicine were significantly improved.However,there was no significant improvement in left ventricular end-diastolic diameter[n=266,MD=-4.50,95%CI(-9.36,0.35),P=0.07].The drug had good safety,and the incidence of hypokalemia could be significantly reduced by traditional Chinese medicine(TCM)treatment[n=177,RR=0.32,95%CI(0.18,0.57),P<0.01].Conclusion On the basis of simple western medicine treatment,modified Zhenwu Decoction can improve 24 h u-rine volume,increase the clinical total effective rate,improve the cardiac function of patients with diuretic resistance in heart failure,reduce the level of inflammatory factors,and have good safety.

Zhenwu DecoctionHeart failureDiuretic ResistanceRandomized Controlled TrialMeta-Analysis

唐娥、王定寅、林姗姗、毕颖斐

展开 >

天津中医药大学第一附属医院,国家针灸临床医学研究中心,天津 300381

天津市中西医结合医院,天津 300100

真武汤 心力衰竭 利尿剂抵抗 随机对照试验 Meta分析

国家中医药管理局中医药创新团队及人才支持计划项目

ZYYCXTD-C-202203

2024

世界中西医结合杂志
中华中医药学会

世界中西医结合杂志

CSTPCD
影响因子:1.053
ISSN:1673-6613
年,卷(期):2024.19(6)